Zheng Rational Drug Design

Methods and Protocols
Erscheinungsjahr 2012
ISBN: 978-1-62703-008-3
Verlag: Humana Press
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band 928, 230 Seiten, eBook

Reihe: Methods in Molecular Biology

Over the past  three decades there have been new developments in therapeutic drug design. In Rational Drug Design: Methods and Protocols,  expert researchers in the field detail many of the methodologies used to study rational drug design. These include methods such as virtual screening of chemical hits, rational lead discovery by high throughput screening, combinatorial and fragment based lead generation, peptide based drug discovery, and animal models of lead validation. Written in the highly successful Methods in Molecular Biology™ series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and key tips on troubleshooting and avoiding known pitfalls.   Authoritative and practical, Rational Drug Design: Methods and Protocols seeks to aid scientists in the further study of rational drug design and future drug discovery.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Zheng, Yi

Inhaltsverzeichnis

On Setting up and Assessing Docking simulations for Virtual Screening.-Virtual Ligand Screening Combined with NMR to Identify Dvl PDZ Domain Inhibitors Targeting the Wnt Signaling.-Rational Design of Rho GTPase Targeting Inhibitors.-Rational Design of Peptide Ligands Against a Glycolipid by NMR Studies.-A Combinatorial Strategy for the Acquisition of Potent and Specific Protein Tyrosine Phosphatase Inhibitors.-Identification of Allosteric Inhibitors of p21-Activated Kinase.-Using a Modified Yeast Two-hybrid System to Screen for Chemical GEF Inhibitors.-Random Mutagenesis of Peptide Aptamers As An Optimization Strategy for Inhibitor Screening.-A Screening Strategy for Trapping the Inactive Conformer of a Dimeric Enzyme with a Small Molecule Inhibitor.-Use of a Fluorescent ATP Analog to Probe the Allosteric Conformational Change in the Active Site of the Protein Kinase PDK1.-Affinity Purification of Protein Kinases that Adopt a Specific Inactive Conformation.-Determination of the Kinetics and Thermodynamics of Ligand Binding to a Specific Inactive Conformation in Protein Kinases.-Purification and Specific Assays for Measuring APE-1 Endonuclease Activity.-An in vitro Screening to Identify Drug Resistant Mutations for Target-directed Chemotherapeutic Agents.-Utilizing AntagomiR (anti-sense microRNA) to Knock Down microRNA in Murine Bone Marrow Cells.-Synthesis, Conjugation, and Labeling of Multifunctional pRNA Nanoparticles for Specific Delivery of siRNA, Drugs and Other Therapeutics to Target Cells.-Mouse Models for Tumor Metastasis.Rational Design of Peptide Ligands Against a Glycolipid by NMR Studies.-A Combinatorial Strategy for the Acquisition of Potent and Specific Protein Tyrosine Phosphatase Inhibitors.-Identification of Allosteric Inhibitors of p21-Activated Kinase.-Using a Modified Yeast Two-hybrid System to Screen for Chemical GEF Inhibitors.-Random Mutagenesis of Peptide Aptamers As An Optimization Strategy for Inhibitor Screening.-A Screening Strategy for Trapping the Inactive Conformer of a Dimeric Enzyme with a Small Molecule Inhibitor.-Use of a Fluorescent ATP Analog to Probe the Allosteric Conformational Change in the Active Site of the Protein Kinase PDK1.-Affinity Purification of Protein Kinases that Adopt a Specific Inactive Conformation.-Determination of the Kinetics and Thermodynamics of Ligand Binding to a Specific Inactive Conformation in Protein Kinases.-Purification and Specific Assays for Measuring APE-1 Endonuclease Activity.-An in vitro Screening to Identify Drug Resistant Mutations for Target-directed Chemotherapeutic Agents.-Utilizing AntagomiR (anti-sense microRNA) to Knock Down microRNA in Murine Bone Marrow Cells.-Synthesis, Conjugation, and Labeling of Multifunctional pRNA Nanoparticles for Specific Delivery of siRNA, Drugs and Other Therapeutics to Target Cells.-Mouse Models for Tumor Metastasis.